The Filing Desk

Gyre Therapeutics vs Zevra Therapeutics

Gyre Therapeutics GYRE · Zevra Therapeutics ZVRA · Pharmaceuticals

Gyre Therapeutics reported revenue of $117 million in fiscal 2025, about the same as Zevra Therapeutics' $106 million in fiscal 2025. Gyre Therapeutics' revenue grew 10.2% in its latest year, and Zevra Therapeutics' grew 350.9%. Gyre Therapeutics had an operating margin of 9.8%, against -59.1% at Zevra Therapeutics. Free cash flow was −$0 million at Gyre Therapeutics and −$2 million at Zevra Therapeutics.

Side by side

Gyre TherapeuticsZevra Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$117M$106M
Revenue growth10.2%350.9%
Revenue growth a year, last 5 years41.0%51.6%
Gross margin95.3%—
Operating margin9.8%−59.1%
Net margin8.5%78.2%
Free cash flow−$0M−$2M
Free cash flow margin−0.1%−2.3%
Return on capital9.7%−218.8%
Net debt to EBITDA−3.8x—
Dividends and buybacks$0M$0M
Change in diluted share count0.9%23.8%
Last close$4.52$9.07
P/E at the last close—7.6×
Insider trades, last 12 monthssold $952,874sold $2.3 million
Piotroski F-score4 of 95 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Gyre TherapeuticsZevra Therapeutics
Operating margin
Percent of revenue
Gyre TherapeuticsZevra Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Gyre TherapeuticsZevra Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Gyre Therapeutics and Zevra Therapeutics pages.